This enhances alflutinib’s activity and kinase selectivity while reducing off-target effects, leading to fewer side effects.146–148 Alflutinib has high selectivity and strong tumor-shrinking properties, with minimal inhibitory effects on wild-type EGFR. The gene discussed is EGFR; the disease is neoplasm.